BUSINESS MODEL
IXILKA BIOTECH provides specific functional new biomolecules as patentable isoforms for use as biomedicine treatments or as reagents for in-vitro diagnostics.
CRAID Methodology has the unique technology capable of producing De-Novo biomolecules (BINDERs) in days instead of years, that can be used as reagent for In-Vitro diagnosis or as biomedicines.
Any person, organization or company may promote a private project, as well as support a CORP as an investor, provided that there is no conflict of interest.
Investors will be entitled to receive 1% of the market capitalization of the biomolecule as reported by the marketer and 0.1% of the potential market spread over the different phases prior to commercialization.
The investor is entitled to have IXILKA BIOTECH provide a free evaluation kit to potential buyers, may participate in the marketing strategy with a vote equivalent to 33% of the final decision, and can access to the raw results obtained in the different tests, studies and experiments that are carried out.
The pharmaceutical industry may acquire a license for the use of any BINDER biomolecule produced by a CORP for industrial or commercial use. Acquirer must pay 0.1% of the potential market distributed in the different pre-commercialization phases and 5% of the market capitalization of the biomolecule. A free functionality evaluation kit will be provided with the license agreement, and payment will only be made when functionality is proven.
